Retinoic Acid News and Research RSS Feed - Retinoic Acid News and Research

Retinoic Acid is a nutrient that that body needs in small amounts to function and stay healthy. All-trans retinoic acid is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. A form of all-trans retinoic acid made in the laboratory is put on the skin to treat conditions such as acne and is taken by mouth to treat acute promyelocytic leukemia (a fast-growing cancer in which there are too many immature blood-forming cells in the blood and bone marrow). All-trans retinoic acid is being studied in the prevention and treatment of other types of cancer. Also called ATRA, retinoic acid, tretinoin, and vitamin A acid.
Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments. [More]
Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment for a range of cancers, researchers at the University of Birmingham have found. [More]
Lycera achieves milestone in Merck research collaboration

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. [More]
Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
Researchers identify previously unknown effect of vitamin A in embryonic development

Researchers identify previously unknown effect of vitamin A in embryonic development

Researchers at Lund University in Sweden have identified a previously unknown effect of vitamin A in human embryonic development. Their findings show that vitamin A affects the formation of blood cells. [More]
NR2F1 gene: A 'master regulator' of tumor cell growth

NR2F1 gene: A 'master regulator' of tumor cell growth

Two existing cancer drugs turn on a gene that tells tumor cells to remain inactive, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published today in Nature Communications. [More]
Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company's lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP). [More]
Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Surgical membrane delivers healing action of vitamin A

Surgical membrane delivers healing action of vitamin A

When blood vessels are damaged through surgery, it can trigger an endless cycle of scarring and repair. [More]

UM researchers explain signaling systems that tissues use to communicate at the head-trunk region

Think about the way our bodies are assembled during early development and ask: How do neighboring cells know that they are supposed to become a nerve or a bone cell and how do these tissues find the correct place and alignment? Researchers at the University of Miami (UM) are answering these crucial questions. [More]

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation. [More]
Lactobacillus-containing probiotics can improve lupus symptoms

Lactobacillus-containing probiotics can improve lupus symptoms

Lactobacillus species, commonly seen in yogurt cultures, correlate, in the guts of mouse models, with mitigation of lupus symptoms, while Lachnospiraceae, a type of Clostridia, correlate with worsening, according to research published ahead of print in Applied and Environmental Microbiology. [More]
AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

Retinoic acid is a form of vitamin A that is used to treat and help prevent the recurrence of a variety of cancers, but for some patients the drug is not effective. [More]
Researchers receive $435K to study how environmental factors affect genes that cause autism

Researchers receive $435K to study how environmental factors affect genes that cause autism

Over the last decade, autism research has been primarily focused on finding genes that may "cause" autism. However, little information exists on gene-environment interactions that may increase risk for autism. [More]
Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives. [More]
Research provides unique insight into lncRNAs that regulate lung development

Research provides unique insight into lncRNAs that regulate lung development

It's a long way from DNA to RNA to protein, and only about two percent of a person's genome is eventually converted into proteins. [More]
Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

At a time when obesity, type 2 diabetes, and their complications are a veritable epidemic worldwide, researchers at the University of Montreal and CHUM Research Centre (CRCHUM) recently demonstrated the potential of retinoic acid (RA), a derivative of Vitamin A, in treating obesity and type 2 diabetes and preventing their cardiovascular complications. [More]
Study reveals loss of function of gene RARRES3 in breast cancer cells promotes metastasis to lung

Study reveals loss of function of gene RARRES3 in breast cancer cells promotes metastasis to lung

A study published today in EMBO Molecular Medicine reveals that the loss of function of the gene RARRES3 in breast cancer cells promotes metastasis to the lung. [More]
Advertisement
Advertisement